Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement
On May 31, 2017, Enumeral Biomedical Holdings, Inc. (“Enumeral”) and Merck Sharp & Dohme Corp. (“Merck”) entered into Amendment No. 2 to Study Agreement (the “Amendment”). The Amendment further amends that certain Study Agreement between Merck and Enumeral, dated as of December 17, 2014 (the “Initial Effective Date”), which was previously amended on February 16, 2016 (as amended, the “Agreement”).
to the Amendment, the term of the Agreement is extended and shall now expire on the earlier of (i) delivery to Merck of the final report of the study conducted to the terms of the Agreement, or (ii) the three (3) year anniversary of the Initial Effective Date, unless extended in writing by mutual agreement. Merck may also terminate the Agreement at any time, with or without cause, effective on ninety days written notice to Enumeral. In addition, the Amendment provides for a revised Work Plan to be included in the Agreement.
The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the three-month period ending June 30, 2017. The Company intends to seek confidential treatment for certain portions of the Amendment.
About Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL)
Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company focused on discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. The Company utilizes a platform technology that facilitates the resolution measurement of immune cell function within small tissue biopsy samples. Its initial focus is on the development of a pipeline of monoclonal antibody drugs targeting established and immuno-modulatory receptors. Its platform technology is a microwell array technology that detects secreted molecules (such as antibodies and cytokines) and cell surface markers at the level of single, live cells and enables recovery of single, live cells of interest. Its program involves antibodies against the Programmed Cell Death receptor, commonly known as (PD-1). In addition to its PD-1 antibody program, it is developing antibody drug candidates for a number of immunomodulatory protein targets, including TIM-3, LAG-3, OX40, TIGIT and VISTA. Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL) Recent Trading Information
Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL) closed its last trading session at 0.150 with shares trading hands.